AGO Algorithms for the Treatment of Breast Cancer: Update 2021
- PMID: 34629489
- PMCID: PMC8494518
- DOI: 10.1055/a-1519-7089
AGO Algorithms for the Treatment of Breast Cancer: Update 2021
Abstract
Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individual cases, other evidence-based treatment options may also be appropriate and justified. Regardless of approval status, the algorithms only take into account drugs that were available in Germany at the time the algorithm was last updated. Here we present the 2021 update of AGO treatment algorithms for early and metastatic breast cancer, which are intended to intensify structured treatment decision by providing reproducible and evidence-based treatment paths and may be helpful for a broad treatment landscape.
Die in den Algorithmen aufgezeigten Behandlungsoptionen basieren zwar auf den aktuellen AGO-Empfehlungen, können aber nicht alle evidenzbasierten Behandlungsoptionen darstellen, da frühere Therapien, der Patientinnenstatus, Begleiterkrankungen, Patientinnenpräferenzen usw. bei der tatsächlichen Therapiewahl mitberücksichtigt werden müssen. Andere evidenzbasierte Behandlungsoptionen können in Einzelfällen auch angemessen und gerechtfertigt sein. Ungeachtet ihres Zulassungsstatus werden nur die Medikamente in den Algorithmen aufgenommen, die zum Zeitpunkt des letzten Algorithmus-Updates in Deutschland zugelassen waren. Die Aktualisierung der AGO-Behandlungsalgorithmen für die Therapie von frühen und metastasierten Brustkrebserkrankungen von 2021 wird hier vorgestellt. Diese Aktualisierung soll strukturierte Behandlungsentscheidungen durch die Darlegung reproduzierbarer, evidenzbasierter Therapiepfade verstärken und kann für eine breit angelegte Behandlungslandschaft nützlich sein.
Keywords: breast cancer guidelines; evidence-based treatment; therapy algorithms.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
Conflict of interest statement
Conflict of Interest Consultancy: Sanofi-Aventis, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Cellgene, Johnson & Johnson, Seagen, MSD, PierreFabre, Amgen, Gilead, DaiichiSankyo. Research Funding: Sanofi-Aventis, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Cellgene, Johnson & Johnson, Seagen, MSD, PierreFabre, Amgen, Gilead, DaiichiSankyo. Honoraria: Sanofi-Aventis, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Cellgene, Johnson & Johnson, Seagen, MSD, PierreFabre, Amgen, Gilead, DaiichiSankyo.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf01.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf02.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf03.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf04.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf05.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf06.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf07.gif)
![Fig. 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8494518/bin/10-1055-a-1519-7089-igf08.gif)
Similar articles
-
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer.Breast Care (Basel). 2020 Dec;15(6):608-618. doi: 10.1159/000511925. Epub 2020 Nov 2. Breast Care (Basel). 2020. PMID: 33447235 Free PMC article. Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.Breast Care (Basel). 2019 Aug;14(4):247-255. doi: 10.1159/000500999. Epub 2019 Jul 30. Breast Care (Basel). 2019. PMID: 31558898 Free PMC article. Review.
-
Clinical Practice Guideline: Sudden Hearing Loss (Update).Otolaryngol Head Neck Surg. 2019 Aug;161(1_suppl):S1-S45. doi: 10.1177/0194599819859885. Otolaryngol Head Neck Surg. 2019. PMID: 31369359
-
Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210. doi: 10.1177/0194599819859883. Otolaryngol Head Neck Surg. 2019. PMID: 31369349
Cited by
-
A Retrospective Multicenter Analysis of Diagon/Gel® 4Two Implant in 209 Cases of Reconstructive Breast Surgery.In Vivo. 2024 Jan-Feb;38(1):380-384. doi: 10.21873/invivo.13449. In Vivo. 2024. PMID: 38148063 Free PMC article.
-
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.Ther Adv Med Oncol. 2023 Sep 28;15:17588359231200454. doi: 10.1177/17588359231200454. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37789989 Free PMC article.
-
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre.Geburtshilfe Frauenheilkd. 2022 Dec 2;83(6):694-701. doi: 10.1055/a-1963-7511. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2022. PMID: 37614685 Free PMC article.
-
Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer-A Retrospective Cohort Study of 161,492 Patients in Germany.Cancers (Basel). 2023 Mar 19;15(6):1847. doi: 10.3390/cancers15061847. Cancers (Basel). 2023. PMID: 36980733 Free PMC article.
-
The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer.Cancers (Basel). 2023 Mar 10;15(6):1704. doi: 10.3390/cancers15061704. Cancers (Basel). 2023. PMID: 36980588 Free PMC article.
References
LinkOut - more resources
Full Text Sources